 | Up a level |
Ferrari, S; Adachi, J D; Lippuner, Kurt; Zapalowski, C; Miller, P D; Reginster, J-Y; Törring, O; Kendler, D L; Daizadeh, N S; Wang, A; O'Malley, C D; Wagman, R B; Libanati, C; Lewiecki, E M (2015). Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporosis international, 26(12), pp. 2763-2771. Springer 10.1007/s00198-015-3179-x
Boonen, S; Adachi, J D; Man, Z; Cummings, S R; Lippuner, K; Törring, O; Gallagher, J C; Farrerons, J; Wang, A; Franchimont, N; San Martin, J; Grauer, A; McClung, M (2011). Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. Journal of clinical endocrinology and metabolism, 96(6), pp. 1727-36. Chevy Chase, Md.: Endocrine Society 10.1210/jc.2010-2784
